Is the Company blinded regarding the average event rates for each group regardless of being blinded on drug vs placebo ? Is it possible they are seeing a difference in the average event rates by statin type ? Could this signal confirmation of data seen in previous post hoc analyses ? I have no idea, merely posing a question .